Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children by Yuji Yasuda et al.
Yuji Yasuda 
Yasuda Clinic, Minami-ku, Kyoto, Japan
Ryoya Komatsu 
Ryoya Komatsu Clinic, Rinku Kita, Izumisano, 
Osaka, Japan
Kenji Matsushita 
Kamoike Seikyou Clinic, Kamoike, Kagoshima, Japan
Taketsugu Minami 
Minami Clinic, Kamoike, Kagoshima, Japan
Yutaka Suehiro 
Saiseikai Nakatsu Hospital, Kita-ku, Osaka, Japan
Hiroshi Sawata · Noriko Nakura 
Novartis Pharma, Minato-ku, Tokyo, Japan
Ralf K. Jaeger 
Novartis Vaccines and Diagnostics, Marburg, Germany
Maria Lattanzi () 
Clinical Development, Novartis Vaccines and 
Diagnostics, Via Fiorentina 1, 53100 Siena, Italy.  
Email: maria.lattanzi@novartis.com
Adv Ther (2010) 27(7):444-457.
DOI 10.1007/s12325-010-0043-4
ORIGINAL RESEARCH
Comparison of Half and Full Doses of an MF59-
Adjuvanted Cell Culture-Derived A/H1N1v Vaccine in 
Japanese Children
Yuji Yasuda · Ryoya Komatsu · Kenji Matsushita · Taketsugu Minami · Yutaka Suehiro · Hiroshi Sawata ·  
Noriko Nakura · Ralf K. Jaeger · Maria Lattanzi
Received: May 7, 2010 / Published online: June 25, 2010
© The Author(s) 2010. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The substantial pandemic 
(A/H1N1v) influenza disease burden in children 
highlights the need for effective vaccination. 
We report the results of modern cell culture 
technology, lower doses of antigen, and different 
doses of MF59® adjuvant (Novartis Vaccines, 




and safety profile in a healthy Japanese 
pediatric population. Methods: A total of 
123 children from 6 months to 19 years of age 
were randomly assigned in a 1:1 ratio to receive, 
at 21-day intervals, two doses of either 3.75 µg 
antigen with 50% of the standard MF59 dose 
(group A) or 7.5 µg antigen and 100% standard 
MF59 dose (group B). Antibody levels were 
measured by hemagglutinin inhibition (HI) 
and microneutralization assays on day 1 and 
on days 22 and 43 (3 weeks after the first and 
second vaccinations, respectively). Solicited 
adverse events were reported for 7 days 
after each injection and spontaneous events 
were reported throughout the study period. 
Results: At 3 weeks after the first vaccination, 
seroprotective HI antibodies (titers ≥40) were 
observed in 56% and 78% of subjects from 
groups A and B, respectively; 100% in both 
groups exhibited HI titers ≥40 after the second 
dose. The reactogenicity profile was acceptable, 
with local and systemic reactions described as 
mainly mild to moderate in severity. Five serious 
adverse events were reported, but none related 
to the study vaccine. Conclusion: One dose of 
cell culture-derived A/H1N1v vaccine containing 
7.5 µg antigen with the full MF59 adjuvant dose 
was immunogenic and well tolerated in healthy 
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Japanese children, meeting all three European 
Union Committee for Medicinal Products for 
Human Use (EU CHMP) licensure criteria. Two 
doses of 3.75 µg antigen with 50% of the standard 
MF59 dose fulfilled these licensure criteria.
Keywords: cell culture vaccine; children; 
A/H1N1v influenza; MF59 adjuvant
INTRODUCTION
In the spring of 2009, a novel influenza A 
(A/H1N1v) virus appeared in Mexico and the US, 
and its resultant spread around the globe has been 
classified as the first pandemic of the twenty-
first century.1,2 As of January 31, 2010, A/H1N1v 
has been identified in humans in more than 
209 countries and caused at least 15,174 deaths.3 
In Japan, a total of 16,570 hospitalizations and 
180 fatal cases have been reported.4 In contrast 
to peak periods of seasonal influenza, when 
influenza hospitalizations are more common 
among persons 65 years of age or older and 
those under the age of 5 years, more than 85% 
of the hospitalizations in Japan occurred in 
people younger than 20 years.4 This trend of 
high percentages of hospitalization in children 
may be explained by a lack of pre-existing 
immunity against the new A/H1N1v virus 
and enhanced transmission opportunities in 
the pediatric population.5 In previous studies, 
influenza vaccination in children has been 
shown to reduce their infection rate as well as 
the virus’s transmission among families and the 
community.6,7 In addition, mass vaccination 
of children may contribute to controlling 
A/H1N1v pandemic influenza.8
Although previous experience with other 
pandemic vaccines has suggested that two doses 
of vaccines for children and adults would be 
needed to induce protection against the new 
A/H1N1v virus strain,9 the results from recently 
published trials in adults have consistently 
demonstrated satisfactory immune responses 
after the administration of only one dose of 
vaccine.10-15 In children, available data are less 
consistent, some studies indicating that a two-
dose administration schedule is needed to 
provide protection in younger children,12,13,15 
while others report effective responses after one 
dose in children aged 6 months to 9 years16 and 
3 to 17 years.17 In the latter study, favorable 
outcomes were reported for a 7.5 µg dose of 
A/H1N1v vaccine with MF59® adjuvant (Novartis 
Vaccines, Marburg, Germany) compared with 
15 µg and 30 µg doses without adjuvant in 
children 3 to 8 years of age.17 Appropriate 
adjuvants may significantly enhance and 
broaden the immune response even with 
reduced antigen content,18-20 with the additional 
benefit of improved cross-reactivity against viral 
mutations,18,20,21 a characteristic of particular 
importance in later phases of a pandemic. 
The use of such adjuvants in 2009 A/H1N1v 
vaccines has been suggested by the World Health 
Organization (WHO).22
There are well documented health disparities 
and increased morbidity and mortality rates from 
influenza among specific ethnic populations 
during the current and previous pandemics.23 
It is therefore important to assess the 
immunogenicity and safety profiles of A/H1N1v 
vaccines over a wide range of ethnic groups. 
The Japanese population may be of particular 
interest, because recent A/H1N1v surveillance 
data show a unique demographic pattern: a low 
case fatality rate and relatively high percentages 
of cases and hospitalizations in children.4
Limitations in vaccine manufacturing 
capacity are a major concern during a period of 
heightened demand, such as during a pandemic. 
Thus, it is essential to consider alternative 
routes, such as modern cell cultivation 
technology, use of adjuvants, and lower antigen 
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dose to increase the availability of vaccines for 
rapid immunization of high-risk populations 
including children, and to ensure the widest 
possible spread of the vaccine supply. The cell 
culture-derived A/H1N1v vaccine in the present 
study is adjuvanted with MF59, an oil-in-water 
emulsion that is a component of the seasonal 
influenza vaccine Fluad® (Novartis Vaccines, 
Siena, Italy), which has been licensed for use in 
adults in the European Union (EU) since 1997, 
and has a confirmed safety profile.24,25
We report the results of a randomized, single-
blind study (part of a larger clinical program in 
Japan) to assess the preferred vaccine dose (of 
antigen and adjuvant) and schedule (one or two 
doses) of a cell culture-derived A/H1N1v vaccine 
(Celtura®, Novartis Vaccines, Marburg, Germany) 
on the immunogenicity, safety, and tolerability 
in a healthy Japanese pediatric population 
between 6 months and 19 years of age.
MATERIALS AND METHODS
This multicenter, single-blind, phase 2/3 
randomized study was performed in five sites 
in Japan between October 2009 and December 
2009. The study was undertaken in compliance 
with Good Clinical Practice guidelines and 
the Declaration of Helsinki. The protocol was 
approved by all local institutional review boards. 
Before enrolment, written informed consent 
was obtained from all parents or legal guardians 
and the participant, if applicable. This trial was 
registered at ClinicalTrials.gov: NCT01000207.
Subjects
A total of 123 healthy Japanese children aged 
6 months to 19 years were enrolled. The main 
exclusion criteria were any history or ongoing 
(chronic) illness likely to interfere with the results, 
any history or likelihood of adverse reactions 
to vaccine components, influenza vaccination 
(except for seasonal influenza at 1 week or more 
apart) or influenza infection in the 3 months 
before enrolment, receipt of any other vaccine 
from 4 weeks before study to completion of 
the study, or any known impairment of the 
immune system. Additional criteria for exclusion 
consisted of a history of progressive or severe 
neurologic disorder, a history of clinically 
suspected development delay, bleeding diathesis, 
or a surgery planned during the study period that 
would interfere with the study visit schedule. 
Negative pregnancy test at day 1 was needed for 
female participants with childbearing potential 
who had used birth control measures for at 
least 2 months before study participation and 
be committed to using birth control measures 
for the whole study duration (3 weeks after the 
second vaccination).
Study Procedures
The children were randomly assigned in a 
1:1 ratio to either group A, in which the subjects 
received the cell-derived A/H1N1v vaccine 
containing 3.75 µg hemagglutinin antigen (HA) 
with 50% of the normal MF59 adjuvant dose, or 
group B in which the subjects received 7.5 µg HA 
with 100% of the normal MF59 dose, a normal 
dose being the amount found in one dose of 
Fluad, the commercially available seasonal 
influenza vaccine. Two vaccinations were 
administered 3 weeks apart. Total study duration 
was 6 weeks with five visits at the clinic. At visit 1 
on day 1 (baseline), each subject was given an 
initial health examination and first blood draw 
(10 mL for immunologic and 5 mL for safety 
analyses for children aged 3-19 years, 5 mL each 
for immunologic and safety analyses, if feasible, 
for children aged 6-35 months). On the same 
day, the first dose of vaccine was administered 
by intramuscular injection in the deltoid muscle 
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of the nondominant arm. For children less than 
12 months of age, vaccine was administered into 
the anterolateral aspect of the thigh. At visit 3 on 
day 22, after a second blood draw, a second dose of 
the same vaccine was administered in the deltoid 
muscle of the other arm. A third blood sample 
was taken at the last visit on day 43 (visit 5). 
Solicited local and systemic reactions were 
collected via diary cards for 1 week following the 
first injection (days 1-7; data collected at visit 2 on 
day 8) and 1 week following the second injection 
(days 22-28, data collected at visit 4 on day 29). 
Spontaneous reports of adverse events (AEs) and 
serious AEs (SAEs) were collected throughout the 
study period.
Vaccines
A single vaccine formulation was used, 
based on A/H1N1v virus cell surface antigen 
(hemagglutinin) prepared by cell cultivation 
in Madin-Darby canine kidney cells26 from the 
seed virus A/California/7/2009 (A/H1N1v)-like 
virus (reassortant virus X 179a) supplied by the 
New York Medical College. This present study 
is one of the clinical trials that contributed to 
the regulatory approval of the study vaccine 
Celtura in Japan. The platform for this drug 
is the same technology used to produce 
the seasonal trivalent inactivated subunit 
vaccine Optaflu® (Novartis Vaccines, Marburg, 
Germany), which is licensed in the EU in 
adults older than 18 years. MF59, is an oil-in-
water emulsion containing naturally occurring 
squalene, as used in the commercial seasonal 
influenza vaccine, Fluad, of which more 
than 40 million doses have been distributed 
so far with a confirmed safety profile in 
adults.24,25 A standard dose of MF59, as used 
in Fluad, contains 9.75 mg squalene, 1.175 mg 
polysorbate 80, and 1.175 mg sorbitan trioleate. 
Vaccines were supplied in monodose, prefilled 
syringes containing a full dose in 0.5 mL (7.5 µg 
HA and full dose of MF59 adjuvant). For the 
appropriate injection for group A, 0.25mL was 
discarded from the prefilled syringe and the 
remaining 0.25 mL was injected into the arm or 
thigh of the participant, equivalent to 3.75 µg 
HA with half dose of MF59 adjuvant. Children 
in group B were administered the full 0.5 mL 
(7.5 µg HA and full dose of MF59 adjuvant).
Immunogenicity Assessment
Blood samples taken for immunologic assays 
at visit 1, 3, and 5 on study day 1, 22, and 43, 
respectively, were centrifuged on the same day, 
and sera were stored at a temperature of −18°C 
or below and shipped to the Novartis Vaccines 
Clinical Serology Laboratory in Marburg, 
Germany, for analysis. Antibody responses were 
measured by hemagglutinin inhibition (HI) and 
microneutralization (MN) assays, according to 
standard methods.27,28 HI antibody responses on 
days 1, 22, and 43 were expressed as geometric 
mean titer (GMTs); geometric mean ratio (GMRs) 
of the postvaccination to prevaccination titer 
(day 22/day 1 titer and day 43/day 1 titer); 
seroprotection rates, defined as the percentage of 
subjects with HI titers ≥40; and seroconversion 
rates, defined as percentage of subjects per group 
achieving at least a fourfold increase in HI titer 
from a seropositive prevaccination titer (≥10) or a 
rise from <10 to ≥40 in those who were originally 
seronegative. The measures of immunogenicity 
as determined by MN are illustrated as GMTs, 
GMRs, percentages with MN titer ≥40, and rates 
of fourfold increases.
Safety Assessment
Subjects were monitored for AEs for 
30 minutes immediately after each injection, 
and local and systemic reactions were recorded 
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on a diary card by the parents or legal guardians 
in the following 7 days until the next study 
visit. All AEs and medications were collected 
throughout the entire study period. For children 
aged 3 to 19 years, the following local reactions 
were reported via diary card: ecchymosis, 
erythema, induration, swelling, and pain at 
injection site. Systemic reactions included 
headache, arthralgia, chills, fatigue, malaise, 
myalgia, nausea, sweating, and fever (ie, a 
temperature ≥38ºC).
For the infants aged 6 to 35 months, local 
reactions reported via diary card included 
ecchymosis, erythema, induration, swelling, 
and tenderness; systemic reactions reported 
via diary card included sleepiness, diarrhea, 
vomiting, irritability, change in eating habits, 
shivering, unusual crying, and fever. Any 
other AEs occurring throughout the duration 
of the study were reported at the subsequent 
study visit, and SAEs had to be reported 
immediately to the study sponsor. A physical 
health assessment was conducted at all visits at 
the site. Vital signs (blood pressure, pulse, and 
body temperature) and clinical laboratory tests 
(hematology, biochemistry, and urinalyses) were 
assessed at study visit 1, 3, and 5 on day 1, 22, 
and 43, respectively.
Statistical Analyses
The sample size of at least 60 subjects in each 
group was chosen to exceed the requirements 
of the European guidelines for yearly influenza 
vaccine clinical trials of at least 50 subjects 
per group.29 There was no formal statistical 
hypothesis tested, immunogenicity endpoints 
being based on HI licensure criteria established 
by the EU Committee for Medicinal Products for 
Human Use (CHMP).29,30 There are no criteria 
for immunogenicity in children established 
by the European Medicines Agency, the 
closest standards are those used for an adult 
population. For subjects aged 18 to 60 years, 
the following criteria apply: (1) the percentage 
of subjects achieving seroprotection, ie, an HI 
titer ≥40 is >70%; (2) percentage of subjects 
with seroconversion or at least fourfold increase 
in HI antibody is >40%; and (3) the GMR is 
>2.5. Immunogenicity data reflecting the above 
endpoints as well as the corresponding two-sided 
95% CIs were calculated for each vaccine group. 
Safety data were evaluated descriptively and 
expressed as proportions or number of subjects 
with AEs in each group.
RESULTS
Of the 123 children enrolled in this study, 
122 (99%) received at least one dose of vaccine 
and 118 (96%) received both doses of vaccines. 
There were 122 and 118 diary cards returned after 
the first and second vaccinations, respectively. 
Demographics of the participants are illustrated 
in Table 1. The mean age was 8.3 years 
(range 0-19 years); 51% of the participants were 
boys and 49% were girls. Body composition 
characteristics and the proportion of subjects 
Table 1. Demographics of the study population.
Group A,  
3.75 µg + 50% 
MF59 (n=61)
Group B,  
7.5 µg + 100% 
MF59 (n=62)
Mean ± SD age, years 8.0±4.6 8.6±5.4
Boys, % 48 55
Girls, % 52 45
Mean ± SD weight, kg 29.4±14.8 30.8±16.5
Mean ± SD height, cm 124.9±28.4 126.2±30.3




BMI= body mass index; MF59=MF59 adjuvant (Novartis 
Vaccines, Marburg, Germany).
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who previously received seasonal influenza 
vaccination (overall 75%) were similar between 
the two groups.
Immunogenicity
HI antibody responses are illustrated in 
Table 2. At baseline, HI titers against the 
vaccine strain were low in both study groups, 
with a GMT of 5.2 for subjects in group A and 
6.2 for those in group B. Only four subjects 
were seroprotected (HI titer ≥40) before 
vaccination. On day 22, 3 weeks after the 
first vaccination, the cell-derived A/H1N1v 
vaccine dose containing 7.5 µg antigen and 
100% MF59 elicited strong immune responses 
and met all three EU CHMP criteria, whereas 
the 3.75 µg dose vaccine only fulfilled two of 
the three criteria. Seroprotection was achieved 
in 56% and 78% of the subjects in groups A 
and B, respectively. The seroconversion rates 
Table 2. Hemagglutinin inhibition (HI) antibody 
responses of the per protocol set for the two groups at 
baseline (day 1), 3 weeks after the first vaccination (day 
22), and 3 weeks after the second vaccination (day 43). 
Numbers in bold represent successful fulfillment of the 
European Union Committee for Medicinal Products for 
Human Use (EU CHMP) licensure criteria.
Group A,  
3.75 µg + 50% 
MF59 (n=57)
Group B,  
7.5 µg + 100% 
MF59 (n=59)
Geometric mean titer (95% CI)
 Day 1 5.2 (4.6, 6.0) 6.2 (5.5, 7.1)
 Day 22 34 (21, 54) 84 (58, 131)
 Day 43 355 (278, 453) 596 (471, 754)
Geometric mean ratio (95% CI)
 Day 22 to day 1 6.4 (4.1, 10.0) 13 (8.7, 21.0)
 Day 43 to day 1 68 (52, 88) 96 (75, 123)
Seroprotection rate (percentage titer ≥40) (95% CI)
 Day 1 0 (0, 6) 7 (2, 16)
 Day 22 56 (42, 69) 78 (65, 88)
 Day 43 100 (94, 100) 100 (94, 100)
Seroconversion rate  
(percentage displaying fourfold increase) (95% CI)
 Day 22 to day 1 56 (42, 69) 78 (65, 88)
 Day 43 to day 1 100 (94, 100) 100 (94, 100)
MF59=MF59 adjuvant (Novartis Vaccines, Marburg, 
Germany).
Figure 1. (A) Percentage of subjects achieving 
seroprotection (hemagglutinin inhibition [HI] titers 
≥40). (B) Percentage of subjects achieving seroconversion 
or at least fourfold increase. (C) Geometric means 
of postvaccination to prevaccination titer ratios 
(geometric mean ratios [GMRs]). Dotted lines in figures 
represent the respective European Union Committee 
for Medicinal Products for Human Use (EU CHMP) 
licensure criteria for adults under 60 years based on HI 
criteria. Day 1 is before vaccination, day 22 is 3 weeks 
after the first injection, and day 43 is 3 weeks after the 
second injection. Results are expressed for total age 
group (6 months-19 years) of the per protocol set. 
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of 56% (group A) and 78% (group B) and 
GMRs of 6.4 (group A) and 13 (group B) were 
all well above the EU CHMP immunogenicity 
requirements of 40% and 2.5, respectively. 
At day 43, 3 weeks after the second vaccine 
administration, further increased and robust 
immunogenic responses were evident in both 
groups, and all subjects exhibited HI titers ≥40 
and seroconversion or a fourfold increase in HI 
antibodies, with GMRs of 68 and 96 in groups 
A and B, respectively (Table 2, Figure 1).
A subanalysis of responses in the two groups 
was performed according to age group (6 to 
35 months; 3 to <9 years; 9 to 19 years), with 
the seroprotection rates illustrated in Figure 2. In 
group B, the youngest (6-35 months) and oldest 
(9-19 years) age groups who received 7.5 µg 
antigen and 100% MF59 met all three EU CHMP 
criteria after the first vaccination (seroprotection 
rates were 91% and 79%; seroconversion 
rates 91% and 79%; and GMRs 17 and 13, 
respectively). Children aged 3 to <9 years who 
received 7.5 µg antigen and 100% MF59 fulfilled 
two of the three criteria (seroconversion rate of 
68% and GMR 10), the seroprotection rate of 
68% missing the criterion of 70% (Figure 2). 
With the lower dose of 3.75 µg antigen and 
50% MF59, all age groups fulfilled two of the 
three criteria after the first vaccination, and 
further increases in rates of seroprotection and 
seroconversion were evident 3 weeks after the 
second vaccination administration, when all 
subjects in all age groups fulfilled all EU CHMP 
licensure criteria.
When considered in respect of previous 
history of influenza vaccination there was 
no difference observed at day 22, after one 
vaccination. Seroprotection rates were 46.2% 
and 87.5% for half-dose and full-dose vaccines, 
respectively, in children with no history of 
vaccination (n=13 and 16), compared with 59.1% 
and 74.4% in those previously vaccinated (n=44 
and 43), 100% of children being seroprotected at 
day 43 after the second injection. As previously 
noted, all subjects had HI titers ≥40 after the 
second vaccination.
Immunogenicity results as determined by 
MN are presented for the total group in Table 3. 
Overall, robust immunogenic responses in both 
vaccine groups were evident, confirming the 
results observed by HI assay. GMTs were low at 
baseline and increased sixfold to 10-fold after 
the first vaccination, and 55-fold to 74-fold 
after the second vaccination in the pooled age 
groups. The proportions of subjects showing 
MN titer ≥40 increased from low baseline 
levels (0% and 7%) to 45% in subjects in group 
A and 59% in those in group B, respectively, 
Figure 2. Percentage of subjects achieving seroprotection (hemagglutinin inhibition [HI] titers ≥40) in the three age groups 
(6-35 months; 3 to <9 years; 9 to 19 years). Numbers in parentheses are n values for each group. The dotted line shows the 
70% criterion for European Union Committee for Medicinal Products for Human Use (EU CHMP) licensure. Error bars 
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7.5 µg HA + 100% MF59
3.75 µg HA + 50% MF59
(9) (11) (19) (19) (29) (29)(19) (19) (29) (29)
Adv Ther (2010) 27(7):444-457. 451
with a further rise to 98% and 100% on day 43. 
Similarly, a fourfold increase was observed 
in 60% (group A) and 74% (group B) of the 
subjects on day 22 and 100% (both groups) on 
day 43.
Safety
Local and systemic reactions reported via 
diary cards during the first 7 days after the first 
and second vaccinations are presented separately 
for the relatively small group of children aged 6 
to 35 months (Table 4) and the children aged 3 
to 19 years (Table 5).
For children aged 6 to 35 months, after both 
the first and second injections 60% in group A 
were reported to have solicited reactions. In 
group B, 55% and 36% were reported to have 
any solicited reaction after the first and second 
vaccination doses, respectively. Erythema was 
the most frequently reported local reaction 
(27% to 30% across groups) and sleepiness 
was the most frequently reported systemic 
reaction (up to 30%), followed by diarrhea 
and vomiting (both up to 10%). Fever (defined 
as a temperature ≥38°C) was present in four 
subjects in each group, with no reports of 
fever ≥40°C.
For the older children, aged 3-19 years, 82% 
and 84% of group A, and 92% and 81% of group B, 
were reported to have any solicited reaction after 
the first and second vaccinations, respectively. 
In subjects at least 3 years of age, local reactions 
consisted mainly of pain at the injection site, 
reported in 64% and 65% of group A, and 82% 
and 63% of group B after the first and second 
vaccinations, respectively, followed by erythema 
(24% to 41% across groups) and swelling (27% 
to 35% across groups).
The most frequently reported systemic 
reactions were fatigue (10% to 22%), headache 
(6% to 22%), and malaise (10% to 21%). Fever 
(≥38°C) was reported in five subjects in group A 
and in eight subjects in group B, but there 
were no reports of fever ≥40°C. In both age 
groups, the frequency and severity of solicited 
reactions did not increase after the second dose 
was administered.
There were a few reports of severe reactions 
on diary cards, consisting of swelling, chills, 
malaise, headache, fatigue, and nausea, which 
all resolved within the observation period 
of 7 days. Use of analgesics was reported in 
two of the ten 6-35-month-old subjects in 
group A (20%) after the second vaccination. 
In 3-19-year-old children, 10% and 8% and 
2% and 6% of groups A and B, respectively, 
reported use of analgesic after the first and 
second vaccinations.
Table 3. Microneutralization (MN) antibody responses 
of the per protocol set. Results are expressed per vaccine 
group at baseline (day 1), 3 weeks after the first injection 
(day 22), and 3 weeks after the second injection (day 43).
 Group A,  
3.75 µg + 50% 
MF59 (n=57)
Group B,  
7.5 µg + 100% 
MF59 (n=59)
GMT (95% CI)
 Day 1 5.2 (4.6, 5.8) 6.03 (5.4, 6.74)
 Day 22 31* (20, 47) 57† (38, 84)
 Day 43 288 (226, 368) 445† (351, 564)
GMR (95% CI)
 Day 22 to day 1 6.0* (4.1, 8.9) 9.8† (6.7, 14)
 Day 43 to day 1 55 (43, 71) 74† (58, 94)
Percentage MN titer ≥40, % (95% CI)
 Day 1 0 (0, 6) 7 (2, 16)
 Day 22 45* (32, 59) 59† (45, 71)
 Day 43 98 (91, 100) 100† (94, 100)
Percentage displaying fourfold increase (95% CI)
 Day 22 to day 1 60* (46, 73) 74† (61, 85)
 Day 43 to day 1 100‡ (94, 100) 100† (94, 100)
*n=55; †n=58; ‡n=57.
GMT=geometric mean titer; GMR=geometric mean 
of postvaccination to prevaccination titer ratios; 
MF59=MF59 adjuvant (Novartis Vaccines, Marburg, 
Germany).
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Reports of spontaneously occurring AEs were 
made for 52% of subjects in group A and 58% in 
group B. Of these, 22% in group A and 29% in 
group B were considered at least possibly vaccine 
related, most of which were classified into general 
disorders and administrative site conditions (13% 
to 18%), the most frequent being injection site 
pruritis (8% to 11%), followed by warmth (2%), 
and pyrexia (0% to 3%). Additional reactions 
that were reported include diarrhea, bronchitis, 
tonsillitis, arthralgia, upper respiratory tract 
inflammation (all up to 2%), and ecchymosis, 
erythema, and rash (2% to 3%).
Five subjects prematurely withdrew from the 
study. Two subjects in group B receiving the 
7.5 µg and 100% MF59 formulation withdrew 
due to a mild to moderate AE; one subject 
reported a rash on study day 1 that resolved after 
2 days and whose relationship with the vaccine 
was not ruled out; the other subject reported 
bronchitis on study day 17 and persisted at the 
time of the withdrawal, which was considered 
Table 4. Solicited local and systemic reactions in 6-35-month-olds after each injection, in each of the vaccine groups.
Dose 1 Dose 2
3.75 µg, 50% 
MF59 (n=10)
7.5 µg, 100% 
MF59 (n=11)
3.75 µg, 50% 
MF59 (n=10)
7.5 µg, 100% 
MF59 (n=11)
Subjects with local site reactions, %
 Ecchymosis Any 20 9 10 0
>100 mm 0 0 0 0
 Erythema Any 30 27 30 27
>100 mm 0 0 0 9
 Induration Any 20 0 10 9
>100 mm 0 0 0 0
 Swelling Any 10 0 20 18
>100 mm 0 0 0 9
 Tenderness Any 0 18 20 18
Cried when injected 
limb was moved
0 0 0 0
Subjects with systemic reactions, %
 Sleepiness Present 30 9 10 0
 Diarrhea Present 0 9 10 9
 Vomiting Present 10 9 0 0
 Irritability Present 10 0 0 0
 Change eating habits Present 20 0 0 0
 Shivering Present 0 0 0 0
 Unusual crying Present 10 0 0 0
 Fever ≥38.0ºC 10 18 30 18
≥40.0ºC 0 0 0 0
Other
 Medication used* Yes 0 0 20 0
*Medication used: antipyretics and analgesics.
MF59=MF59 adjuvant (Novartis Vaccines, Marburg, Germany).
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Table 5. Solicited local and systemic reactions in 3-19-year-olds after each injection, in each of the vaccine groups.
Dose 1 Dose 2
3.75 µg, 50% 
MF59 (n=50)
7.5 µg, 100% 
MF59 (n=51)
3.75 µg, 50% 
MF59 (n=49)
7.5 µg, 100% 
MF59 (n=48)
Subjects with local site reactions, %
 Ecchymosis Any 6 8 4 13
>100 mm 0 0 0 0
 Erythema Any 32 41 24 25
>100 mm 0 0 0 0
 Induration Any 18 24 14 17
>100 mm 0 0 0 0
 Swelling Any 28 35 27 33
>100 mm 0 0 2 0
 Pain Any 64 82 65 63
Severe 0 0 0 0
Subjects with systemic reactions, %
 Chills Any 4 8 2 6
Severe 0 4 0 2
 Malaise Any 14 16 10 21
Severe 2 4 2 2
 Myalgia Any 8 18 6 13
Severe 0 0 0 0
 Arthralgia Any 2 8 0 2
Severe 0 0 0 0
 Headache Any 22 22 6 17
Severe 2 2 0 2
 Sweating Any 2 2 2 0
Severe 0 0 0 0
 Fatigue Any 16 22 10 13
Severe 0 2 2 0
 Nausea Any 2 8 6 2
Severe 2 0 0 0
 Fever ≥38.0ºC 8 10 2 6
≥40.0ºC 0 0 0 0
Other
 Stayed at home Yes 4 4 0 4
 Medication used* Yes 10 8 2 6
*Medication used: antipyretics and analgesics.
MF59=MF59 adjuvant (Novartis Vaccines, Marburg, Germany).
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not vaccine related. One subject withdrew 
from group A with mild pyrexia 3 days after 
vaccination, which resolved within 3 days. Two 
other subjects withdrawn from group A were 
reported with swine influenza and influenza A, 
respectively. Five SAEs were reported (four cases 
of influenza and a fracture of the left humerus), 
none of which were considered related to the 
study vaccine. The influenza cases involved 
one subject who was reported to have swine 
influenza for a duration of 15 days 7 days after 
receiving their first vaccination with the lower- 
dose vaccine, and two subjects who received 
the full dose vaccine who had influenza A for 
a duration of 4 days from study days 6 and 25, 
respectively, and one subject given the full dose 
who had influenza B for a duration of 7 days 
from study day 20.
DISCUSSION
Seasonal influenza and the current 
2009 pandemic A/H1N1v influenza are associated 
with substantial morbidity and hospitalizations 
in the pediatric population, highlighting the 
need for effective vaccination in these younger 
age groups.4,31,32 In the present study, we report 
the results of novel and dose-sparing strategies 
in influenza vaccine development, on the 
immunogenicity and safety profile in a healthy 
Japanese pediatric population aged 6 months 
to 19 years. Findings of the present study 
show that one dose of the cell culture-derived 
A/H1N1v vaccine Celtura, containing 7.5 µg of 
antigen supplemented with the full amount of 
MF59 adjuvant, elicited robust immunogenic 
responses in a Japanese pediatric population 
aged 6 months to 19 years, which met all three 
EU CHMP licensure criteria. Administration 
of a half dose of this vaccine (3.75 µg HA 
together with 50% of the normal dose of the 
MF59 adjuvant) fulfilled two of the three EU 
CHMP criteria 3 weeks after the first vaccination 
dose, while a second vaccination resulted in all 
subjects achieving all three EU CHMP criteria 
3 weeks later.
Results expressed for the specific age groups 
indicate that two doses of vaccine might be 
needed in children aged 3 to <9 years to provide 
sufficient protection. However, the separate age 
groups in this study consisted of relatively small 
numbers of subjects (n=9-29), so these results 
should be interpreted with caution.
Both doses of vaccine were well tolerated, and 
the reactogenicity and safety profiles were in line 
with previous studies using MF59-adjuvanted 
vaccines in a pediatric population.28,33 The 
majority of AEs were mild to moderate in severity, 
and none of the five reported SAEs were vaccine 
related. To elucidate the full safety profile of 
A/H1N1v vaccines, postmarketing surveillance 
will be required.
Before the first vaccination, only four 
subjects exhibited protective HI titers ≥40 
against the novel A/H1N1v influenza virus. 
These low baseline antibody titers are in line 
with recently published studies from the US 
and China,12,13 but are noticeably lower than 
the reported percentages from an Australian 
study, in which 27% to 33% of the children 
aged ≥3 years exhibited seroprotective titers at 
baseline. Although local A/H1N1v influenza 
activity was present in Japan during the study, 
and illustrated by the three subjects who were 
reported with swine influenza or influenza A, 
subclinical exposure to the virus was probably 
ruled out by the stringent exclusion criteria.
Today, both the UK and the US have guidelines 
that recommend administration of two vaccines 
for pandemic influenza.34,35 However, in line 
with our findings, recently published trials 
in adults, the elderly, and children suggest 
that a single-dose vaccine regimen against the 
A/H1N1v virus strain may be effective and well 
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tolerated.10,11,14,17 The pediatric trials that reported 
satisfactory immune responses after only one 
dose used a nonadjuvanted split-virion vaccine 
containing 15 or 30 µg of antigen per dose16 or 
an egg-based A/H1N1v vaccine containing 15 
or 30 µg antigen per dose without adjuvant, or 
7.5 µg antigen with MF59 adjuvant.17 In this 
latter study, however, only the 7.5 µg HA with 
MF59 adjuvant met the immunogenicity criteria 
after one dose in children 3 to 8 years of age.17 
The immunogenic responses observed after one 
vaccination differ from those of earlier studies 
in seasonal H1 strains, and in H5N1 vaccination 
studies where two doses were required to 
induce sufficient immunogenic protection.19,34 
Differences may be related to specific antigen 
characteristics of the new A/H1N1v strain that 
have yet to be determined. In addition, and 
particularly in children, the use of appropriate 
adjuvants may have contributed to the robust 
immune response observed after one dose of 
the 7.5 µg antigen dose containing the full 
MF59 dose.
In previous studies, the MF59-adjuvanted 
influenza vaccine has been shown to provide 
higher immunogenicity compared with 
nonadjuvanted vaccines, particularly in those 
with low prevaccination antibody titers, with 
a good safety profile in vulnerable populations 
including the elderly, adults with underlying 
chronic conditions, and children.21,24,25,28,33 In 
addition, the MF59-adjuvanted vaccines induced 
broader immunogenicity than conventional 
vaccines against drifted strains,28,33 which may 
be of particular importance in later phases of 
a pandemic.
The data from our study do not provide 
any clear-cut answers for the most effective 
vaccination strategy in children. However, 
our findings suggest that one dose of a cell-
cultivated A/H1N1v vaccine containing 7.5 µg 
HA and 100% MF59 is effective and well 
tolerated in a pediatric population, which 
may have important implications for disease 
protection and reduced influenza transmission. 
The use of MF59 adjuvants allows dose sparing, 
which is an important ethical and moral public 
health issue to consider in periods of heightened 
demand. Additional potential advantages of 
the adjuvant, particularly the enhanced cross-
reactivity and long-term priming, as previously 
demonstrated for H5N1 vaccines,20,24 will only 
be determined with longer experience of the 
novel A/H1N1v  virus strain.
CONCLUSION
A single dose of a cell culture-derived 
A/H1N1v vaccine containing 7.5 µg of antigen 
formulated with the full MF59 adjuvant dose, 
elicited robust immunogenic responses in a 
Japanese pediatric population aged 6 months to 
19 years, was well tolerated, and met all three 
EU CHMP licensure criteria. At 3 weeks after the 
second vaccination dose, subjects who received a 
half dose of this formulation (3.75 µg of antigen) 
also fulfilled the three licensure criteria.
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